The earliest stages of biological drug development are often where the foundations for future success are established. While scientific innovation remains essential, investors also evaluate a range of factors that can influence a project’s long-term potential, development trajectory, and ability to attract future funding.
Understanding what drives investment decisions at this stage can help researchers and emerging companies strengthen their strategies and position their projects for sustainable growth.
In this webinar, Fredrik Lehmann, life science professional and investor, will share perspectives on what investors look for in the earliest phases of biological drug development.
The discussion will explore key considerations in early-stage development, how to build a stronger foundation for future growth, and strategic approaches for navigating the transition from research to development.
Register here: LINK
The Bridge webinar series is aimed at researchers, start-up and scale-up companies, and organisations within the innovation support system engaged in the development of biological products and pharmaceuticals.
